Interesting quarterly with plenty of new tidbits in there. Whilst frustratingly slow, it does seem as though the HCD tentacles are spreading.
Still bleeding cash with a little over 4 quarters remaining, however one or more big sales could ease that.
Lots to look forward to provided all these tests & trials equate to a lovely flow of moolah.
